Silexion Therapeutics Ltd. (SLXN) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
The Goldyne Savad Institute of Gene Therapy
Jerusalem, 9112001
Israel
Phone
972 2 674 3430
Website
Sector
Healthcare
Industry
Biotechnology
Employees
11
First IPO Date
August 16, 2024
| Name | Title | Pay | Year Born |
| Ilan Hadar | Chairman & Chief Executive Officer | 347,843 | 1969 |
| Mitchell Shirvan | Chief Scientific & Development Officer | 257,791 | 1954 |
| Mirit Horenshtein Hadar | EVice President of Finance Affairs, Chief Financial Officer & Secretary | 322,799 | 1984 |
Silexion Therapeutics LTD is a biopharmaceutical company specializing in the discovery and advancement of RNA interference (RNAi)-based cancer therapies and their associated delivery systems, with a focus on treating aggressive solid tumors. The company's strategy for addressing these tumors relies on its proprietary LODER delivery platform. Its product pipeline features several key candidates: SiG12D-LODER, which has progressed through both preclinical studies and an open-label Phase I clinical trial for pancreatic cancer; Prostate-LODER, currently undergoing preclinical evaluation for prostate cancer; and GBM-LODER, also in preclinical development, targeting Glioblastoma Multiforme, a highly malignant primary brain tumor. Founded in 2008, Silexion Therapeutics is headquartered in Jerusalem, Israel.